First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

OBJECTIVE: The aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy (CT) compared to EGFR-TKI monotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC) harbor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qiang, Luo, Wuxia, Li, Wen, Wang, Ting, Huang, Lin, Xu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076535/
https://www.ncbi.nlm.nih.gov/pubmed/33928022
http://dx.doi.org/10.3389/fonc.2021.598265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076535/
https://www.ncbi.nlm.nih.gov/pubmed/33928022
http://dx.doi.org/10.3389/fonc.2021.598265

Ejemplares similares